» Articles » PMID: 29860718

Radiosensitizing Effects of MiR-18a-5p on Lung Cancer Stem-like Cells Via Downregulating Both ATM and HIF-1α

Overview
Journal Cancer Med
Specialty Oncology
Date 2018 Jun 4
PMID 29860718
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is one of the main causes of cancer mortality globally. Most patients received radiotherapy during the course of disease. However, radioresistance generally occurs in the majority of these patients, leading to poor curative effect, and the underlying mechanism remains unclear. In the present study, miR-18a-5p expression was downregulated in irradiated lung cancer cells. Overexpression of miR-18a-5p increased the radiosensitivity of lung cancer cells and inhibited the growth of A549 xenografts after radiation exposure. Dual luciferase report system and miR-18a-5p overexpression identified ataxia telangiectasia mutated (ATM) and hypoxia inducible factor 1 alpha (HIF-1α) as the targets of miR-18a-5p. The mRNA and protein expressions of ATM and HIF-1α were dramatically downregulated by miR-18a-5p in vitro and in vivo. Clinically, plasma miR-18a-5p expression was significantly higher in radiosensitive than in radioresistant group (P < .001). The cutoff value of miR-18a-5p >2.28 was obtained from receiver operating characteristic (ROC) curve. The objective response rate (ORR) was significantly higher in miR-18a-5p-high group than in miR-18a-5p-low group (P < .001). A tendency demonstrated that the median local progression-free survival (PFS) from radiotherapy was longer in miR-18a-5p-high than in miR-18a-5p-low group (P = .082). The median overall survival (OS) from radiotherapy was numerically longer in miR-18a-5p-high than in miR-18a-5p-low group (P = .281). The sensitivity and specificity of plasma miR-18a-5p to predict radiosensitivity was 87% and 95%, respectively. Collectively, these results indicate that miR-18a-5p increases the radiosensitivity in lung cancer cells and CD133 stem-like cells via downregulating ATM and HIF-1α expressions. Plasma miR-18a-5p would be an available indicator of radiosensitivity in lung cancer patients.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.


Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells.

Shi Z, Hu C, Zheng X, Sun C, Li Q Exp Hematol Oncol. 2024; 13(1):55.

PMID: 38778409 PMC: 11110349. DOI: 10.1186/s40164-024-00519-1.


Cancer stem cells: a target for overcoming therapeutic resistance and relapse.

Zhang S, Yang R, Ouyang Y, Shen Y, Hu L, Xu C Cancer Biol Med. 2024; .

PMID: 38164743 PMC: 10845928. DOI: 10.20892/j.issn.2095-3941.2023.0333.


Connection between Radiation-Regulating Functions of Natural Products and miRNAs Targeting Radiomodulation and Exosome Biogenesis.

Tang J, Chuang Y, Shiau J, Yen C, Chang F, Tsai Y Int J Mol Sci. 2023; 24(15).

PMID: 37569824 PMC: 10419287. DOI: 10.3390/ijms241512449.


MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?.

Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X Biomolecules. 2023; 13(6).

PMID: 37371458 PMC: 10295928. DOI: 10.3390/biom13060877.


References
1.
Morrison A, Highland J, Krogan N, Arbel-Eden A, Greenblatt J, Haber J . INO80 and gamma-H2AX interaction links ATP-dependent chromatin remodeling to DNA damage repair. Cell. 2004; 119(6):767-75. DOI: 10.1016/j.cell.2004.11.037. View

2.
Liu S, Pan X, Yang Q, Wen L, Jiang Y, Zhao Y . MicroRNA-18a enhances the radiosensitivity of cervical cancer cells by promoting radiation-induced apoptosis. Oncol Rep. 2015; 33(6):2853-62. DOI: 10.3892/or.2015.3929. View

3.
Hatano K, Kumar B, Zhang Y, Coulter J, Hedayati M, Mears B . A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Res. 2015; 43(8):4075-86. PMC: 4417178. DOI: 10.1093/nar/gkv273. View

4.
Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C . MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013; 8(10):e76994. PMC: 3805541. DOI: 10.1371/journal.pone.0076994. View

5.
Lin S, Sun J, Wu J, Long H, Zhu C, Xiang T . Aberrant microRNAs expression in CD133⁺/CD326⁺ human lung adenocarcinoma initiating cells from A549. Mol Cells. 2012; 33(3):277-83. PMC: 3887701. DOI: 10.1007/s10059-012-2252-y. View